Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643574 | 0.76 | MAP3K14 (0.43) | LRRK2MAP3K14TTKJAK2JAK1 | |
| SCHEMBL30644402 | 0.76 | MAP3K14 (0.43) | LRRK2MAP3K14TTKJAK2JAK1 | |
| SCHEMBL12795371 | 0.76 | JAK3 (0.40) | LRRK2TTKCYP1A2 | |
| SCHEMBL2591069 | 0.74 | JAK3 (0.48) | MAP3K14 | |
| SCHEMBL12797397 | 0.72 | TTK (0.38) | LRRK2MAP3K14TTKJAK2JAK1 | |
| SCHEMBL12797299 | 0.72 | JAK3 (0.35) | LRRK2MAP3K14TTKJAK2JAK1 | |
| SCHEMBL1662817 | 0.71 | EIF2AK4 (0.45) | LRRK2TTK | |
| SCHEMBL2122067 | 0.71 | GLO1 (0.55) | LRRK2 | |
| SCHEMBL31691121 | 0.70 | MAP3K14 (0.41) | LRRK2MAP3K14TTK | |
| SCHEMBL30644467 | 0.70 | MAP3K14 (0.39) | LRRK2MAP3K14TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | LRRK2 2904/4885MAP3K14 189/4885TTK 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.